Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1991 1
1992 1
1995 1
1997 1
2004 2
2006 2
2007 1
2008 1
2009 6
2010 2
2011 2
2012 2
2013 2
2014 1
2015 2
2016 4
2017 8
2018 9
2019 4
2020 5
2021 3
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
A national precision cancer medicine implementation initiative for Norway.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. Taskén K, et al. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. Nat Med. 2022. PMID: 35513529 No abstract available.
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D, Hjortland GO, Hovig E, Hovland R, Iversen AC, Janssen E, Kyte JA, von der Lippe Gythfeldt H, Lothe R, Lund JÅ, Meza-Zepeda L, Munthe-Kaas MC, Nguyen OTD, Niehusmann P, Nilsen H, Puco K, Ree AH, Riste TB, Semb K, Steinskog ESS, Stensvold A, Suhrke P, Tennøe Ø, Tjønnfjord GE, Vassbotn LJ, Aas E, Aasebø K, Tasken K, Smeland S. Helland Å, et al. Among authors: lund ja. J Transl Med. 2022 May 14;20(1):225. doi: 10.1186/s12967-022-03432-5. J Transl Med. 2022. PMID: 35568909 Free PMC article. Clinical Trial.
In Reply to Sari et al.
Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ. Aksnessæther BY, et al. Among authors: lund ja. Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):388-389. doi: 10.1016/j.ijrobp.2020.02.027. Epub 2020 Feb 26. Int J Radiat Oncol Biol Phys. 2020. PMID: 32112877 No abstract available.
Adverse events of undiluted intravenous push levetiracetam.
Summerlin JA, Scaturo N, Lund JA, Wang KM, Frank MA. Summerlin JA, et al. Among authors: lund ja. Am J Emerg Med. 2023 Nov;73:182-186. doi: 10.1016/j.ajem.2023.08.046. Epub 2023 Sep 4. Am J Emerg Med. 2023. PMID: 37708595
Response to Alongi et al.
Tøndel H, Lund JÅ, Solberg A. Tøndel H, et al. Among authors: lund ja. Radiother Oncol. 2018 Aug;128(2):391. doi: 10.1016/j.radonc.2018.05.008. Epub 2018 Jun 12. Radiother Oncol. 2018. PMID: 29907339 No abstract available.
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D, Hjortland GO, Hovig E, Hovland R, Iversen AC, Janssen E, Kyte JA, von der Lippe Gythfeldt H, Lothe R, Lund JÅ, Meza-Zepeda L, Munthe-Kaas MC, Nguyen OTD, Niehusmann P, Nilsen H, Puco K, Ree AH, Riste TB, Semb K, Steinskog ESS, Stensvold A, Suhrke P, Tennøe Ø, Tjønnfjord GE, Vassbotn LJ, Aas E, Aasebø K, Tasken K, Smeland S. Helland Å, et al. Among authors: lund ja. J Transl Med. 2022 Jul 15;20(1):317. doi: 10.1186/s12967-022-03518-0. J Transl Med. 2022. PMID: 35841045 Free PMC article. No abstract available.
Second cancers in radically treated Norwegian prostate cancer patients.
Aksnessæther BY, Lund JÅ, Myklebust TÅ, Klepp OH, Skovlund E, Roth Hoff S, Solberg A. Aksnessæther BY, et al. Among authors: lund ja. Acta Oncol. 2019 Jun;58(6):838-844. doi: 10.1080/0284186X.2019.1581377. Epub 2019 Mar 25. Acta Oncol. 2019. PMID: 30905229
The management and survival outcomes of nasopharyngeal cancer in the Nordic countries<sup/>
Mäkitie A, Ruuskanen M, Bentzen J, Brun E, Gebre-Medhin M, Friesland S, Marsk E, Hammarstedt-Nordenvall L, Gille E, Reizenstein J, Adell G, Farnebo L, Rzepecki J, Haugen H, Söderström K, Zackrisson B, Bergström S, Lödén B, Cederblad L, Laurell G, Smeland E, Folkvard Evensen J, Lund JÅ, Tøndel H, Karlsdottir Å, Jóhannsson J, Johansen J, Kristensen CA, Jensen K, Andersen LJ, Koivunen P, Korpela M, Voutilainen L, Wigren T, Minn H, Joensuu H, Overgaard J, Saarilahti K. Mäkitie A, et al. Among authors: lund ja. Acta Oncol. 2018 Apr;57(4):557-560. doi: 10.1080/0284186X.2017.1408961. Epub 2017 Dec 5. Acta Oncol. 2018. PMID: 29202641 No abstract available.
60 results